arrow
G

George S. Vassiliou

wellcome mrc cambridge stem cell institute
H指数:59
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacological inhibition of METTL1 as a therapy against solid and blood cancers

METTL1的药理学抑制作为对抗实体瘤和血液癌的疗法

Nature
IF48.5
2026-10-280
OAAI
Transferrin in combination with induction chemotherapy improves outcomes in mouse models of acute myeloid leukemia

转铁蛋白联合诱导化疗可改善急性髓系白血病小鼠模型的预后

2026-06-240
PRE
The prevalence and clinical significance of clonal monocytosis

克隆性单核细胞增多的患病率及临床意义

Blood
IF23.1
2026-03-100
OA
A disease model resource reveals core principles of tissue-specific cancer evolution

一个疾病模型资源揭示了组织特异性癌症演化的核心原则

Nature
IF48.5
2026-02-250
OAAI
CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer

CDK7-targeted疗法可有效破坏头颈癌的细胞周期进程和致癌信号传导

2025-11-060
OAAI
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis

端粒损耗成为衰老造血和白血病发生过程中克隆选择的一种机制。

2025-08-280
OAAI
Post-transcriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML

转录后耗竭核糖体生物发生因子在NPM1突变AML中产生治疗易感性

Blood
IF23.1
2025-06-270
OA
Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein

通过靶向细胞表面RNA结合蛋白对急性髓系白血病模型的治疗

2025-04-230
OA
Mutagenic DNA Lesions in Normal Hematopoietic Stem Cells Persist for Years Causing Distinct Patterns of Mutation

正常造血干细胞中的致突变DNA损伤持续数年并导致特异的突变模式

BLOOD
IF23.1
2024-11-050
PRE
SOD1 is a synthetic-lethal target in PPM1D-mutant leukemia cells
2024-06-180
OA
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

关于多发性骨髓瘤先兆临床试验优化设计的圆桌讨论

2024-05-012
OA
Investigating the role of the somatic DDX41 variant in the context of DDX41 hereditary myeloid malignancy syndromes (HMMS)
2024-02-010
PRE